

Dr. T's Super Charged Omega



Clinical Applications

- Positively Affects the Production of Arachidonic Acid-Derived Eicosanoids*
- Supports Cardiovascular Health*
- Supports Healthy Mental Functioning*
- Supports Healthy Glucose and Insulin Metabolism*
- By Supplying the Precursors EPA and DHA, Helps the Body Generate Specialized Proresolving Lipid Mediators, Such as Resolvins and Protectins*

The Dr. T's Super Charged Omega family of formulas feature MaxSimil® monoglyceride fish oil that has a three times greater EPA+DHA absorption rate than an equivalent dose of other leading fish oils. Through the use of MaxSimil patented lipid absorption enhancement technology (PLATform), the fish oil is absorption-ready and can be directly assimilated in the intestinal tract for maximum benefit. Arthricor® olive extract, found in Dr. T's Super Charged Omega MD, provides additional cardiovascular support.*

All O Health by D. T Formulas Meet or Exceed cGMP Quality Standards


Manufactured from: O Health by D. T.
600 N. Hiatus Road, S-201
Pembroke Pines, FL 33026
954-526-6378

Discussion

MaxSimil® Patented Lipid Absorption Enhancement Technology (PLATform)

The MaxSimil PLATform is a novel monoglyceride delivery system that enhances absorption of lipid-based and lipid-soluble nutraceutical and food ingredients. This technology has been applied to O Health by D. T's Dr. T's Super Charged Omega formulas in order to create a unique vehicle by which to deliver EPA and DHA. Due to the fact that monoglyceride oils are intrinsically emulsifiers and are, by nature, in a readily absorbable form, they can bypass the body's normal fat digestion process. These qualities make Dr. T's Super Charged Omega an excellent method for delivering omega-3 fatty acids, especially to individuals with digestive, pancreatic, or gall bladder challenges. Studies show that MaxSimil fish oils (FO) have three times (300%) greater absorption of EPA and DHA compared to other leading fish oils.*^[1-3]

Figure 1. Monoglyceride Chemical Representation in MaxSimil Fish Oils (R1 = fatty acid)



Unique structure: One fatty acid attached to a glycerol backbone provides two polar ends that attract water and a non-polar tail end (R1) that attracts fat, thus enabling self-emulsification of the Dr. T's Super Charged Omega formulas.

Reprinted with permission from Ingenutra, Inc.

Quality

Dr. T's Super Charged Omega formulas are made using proprietary MaxSimil compositions containing monoglyceride FO with no additional ingredients, carriers, or excipients. Each fish-gelatin softgel is enteric-coated, and every batch of fish oil ensure the world's highest standards for purity, potency, and freshness. The fish oil is non-GMO, certified sustainable from Scandinavia, and antibiotic-free. Additionally, it is eco-friendly because the greater absorption of EPA and DHA ultimately means that fewer grams of fish oil need to be harvested for the same benefit.*

Continued on next page

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Dr. T's Super Charged Omega



Clinical Bioavailability Study

A phase 1, double-blind, randomized, crossover, pharmacokinetic study was performed in 20 healthy adults aged between 19 and 71 years who were administered 6 g (containing 1800 mg EPA and 1200 mg DHA) per day of EE FO or MaxSimil FO.^[3] Parameters studied were plasma EPA and DHA concentration (as percent of total fatty acids), C_{max}, and AUC. Compared to EE EPA+DHA, the results indicated that at peak concentration, MaxSimil EPA and DHA forms were 3x higher, they reached maximum concentration faster, and maintained their plasma levels longer. The finding in the animal study was validated: the MaxSimil FO instantaneous absorption was 3x greater than the EE form. Likewise, the AUC over 24 hours was also more than 3x higher (P<.0001) for MaxSimil EPA and DHA (MaxSimil FO).*

A Note About Resolvins and Other EPA and DHA Metabolites

Specialized proresolving lipid mediators, such as resolvins, protectins, and maresins, are EPA and DHA metabolites naturally produced in vivo through enzymatic conversion of EPA and DHA. These mediators aid the body's "clean-up" response to the arachidonic acid cascade.^[13] Rather than supplying a single molecule or metabolite, which would mirror the pharmaceutical model, Dr. T's Super Charged Omega fish oils provide all the benefits of EPA and DHA as well as the expected and desirable benefits of their metabolites.*

Arthricor[®]: Dr. T's Super Charged Omega MD

Each softgel of Dr. T's Super Charged Omega MD provides 500 mg of MaxSimil FO combined with 50 mg


of Arthricor olive leaf extract. It is generally accepted that the is beneficial to cardiovascular health,^[14-16] and research suggests that olive oil and its phenolic constituents are primary contributors.^[17-21] Taking Arthricor olive leaf extract daily provides the polyphenolic benefits of eating five olives or 50 mL of olive oil each day. Phenolic compounds, as found in Arthricor, have been shown to have a protective effect against LDL oxidation.^[19,22,23] Arthricor provides three polyphenols—hydroxytyrosol, oleuropein, and tyrosol—for maximum benefit.*

Continued on next page

*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.



Figure 3. Human Clinical Study Findings Demonstrate Superior Absorption of and Exposure to EPA and DHA as Indicated by Cmax, Tmax, and AUC



Reprinted with permission from Ingenutra, Inc.

Dr. T's Super Charged Omega

Supplement Facts

Serving Size: 1 Softgel
Servings Per Container: 60

	Amount Per Serving	%Daily Value
Calories	5	
Total Fat	0.5 g	1%†
MaxSimil® Fish Oil Concentrate	500 mg	**
Total Omega-3 Fatty Acids	330 mg	**
EPA (eicosapentaenoic acid)	230 mg	**
DHA (docosahexaenoic acid)	100 mg	**
Arthricor® Olive Extract (<i>Olea europaea</i>)(leaves) (9% hydroxytyrosol, 4% oleuropein, 1% tyrosol)	50 mg	**

† Percent Daily Values are based on a 2,000 calorie diet.
** Daily Value not established.

Other Ingredients: Softgel (fish gelatin, vegetable glycerin, purified water, and carob extract), GRAS enteric coating (ethylcellulose, sodium alginate, purified water, medium-chain triglycerides, oleic acid, vegetable stearic acid, and ammonium hydroxide), beeswax, sunflower lecithin, maltodextrin, silica, and mixed natural tocopherols.

Contains: Fish (anchovy and/or sardine [sources of fish oil], tilapia and/or pangasius [sources of fish gelatin]).

Manufactured using MaxSimil® fish oil. MaxSimil® is a registered trademark of Ingenutra Inc. Protected under US patents 8,119,690 and 8,198,324; Canadian patents 2672513 and 2677670.

Arthricor is a trademark of Eight-IP.

Dr. T's Super Charged Omega

Supplement Facts

Serving Size: 1 Softgel
Servings Per Container: 60

	Amount Per Serving	%Daily Value
Calories	10	
Total Fat	1 g	1%†
MaxSimil® Fish Oil Concentrate	1.3 g	**
Total Omega-3 Fatty Acids	860 mg	**
EPA (eicosapentaenoic acid)	600 mg	**
DHA (docosahexaenoic acid)	260 mg	**

† Percent Daily Values are based on a 2,000 calorie diet.

** Daily Value not established.

Other Ingredients: Softgel (fish gelatin, vegetable glycerin, and purified water), GRAS enteric coating (ethylcellulose, sodium alginate, purified water, medium-chain triglycerides, oleic acid, vegetable stearic acid, and ammonium hydroxide), and mixed natural tocopherols.

Contains: Fish (anchovy and/or sardine [sources of fish oil], tilapia and/or pangasius [sources of fish gelatin]).

Manufactured using MaxSimil® fish oil. MaxSimil® is a registered trademark of Ingenutra Inc. Protected under US patents 8,119,690 and 8,198,324; Canadian patents 2672513 and 2677670.

Directions

Take one softgel daily, or use as directed by your healthcare practitioner.

Consult your healthcare practitioner prior to use. Individuals taking blood thinners or other medication should discuss potential interactions with their healthcare practitioner. Do not use if tamper seal is damaged.

Does Not Contain

Wheat, gluten, corn, yeast, soy protein, dairy products, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or artificial preservatives.

Directions

Take one softgel daily, or use as directed by your healthcare practitioner.

Consult your healthcare practitioner prior to use. Individuals taking blood thinners or other medication should discuss potential interactions with their healthcare practitioner. Do not use if tamper seal is damaged.

Does Not Contain

Wheat, gluten, corn, yeast, soy protein, dairy products, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or artificial preservatives.

***These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.**



References

1. Unpublished, internal data. Ingenutra.
2. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof. US patent 8,198,324. June 12, 2012.
3. MaxSimil Patented Lipid Absorption Technology Clinical Study Report: MaxSimil® 3020 Omega-3. Sherbrooke (Québec), Canada: Ingenutra; 2015. [Unpublished, internal data]
4. Morin C, Rousseau É, Fortin S. Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells. *Prostaglandins Leukot Essent Fatty Acids*. 2013 Sep;89(4):203-13. [PMID: 23932824]
5. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US patent 8,119,690. February 21, 2012.
6. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US patent 8,329,747. December 11, 2012.
7. Morin C, Blier PU, Fortin S. Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to resolve inflammation in a rheumatoid arthritis model. *Arthritis Res Ther*. 2015 May 29;17:142. [PMID: 26022389]
8. Morin C, Fortin S, Cantin AM, et al. Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: implication of PKC-Potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kD in asthma. *Am J Respir Cell Mol Biol*. 2011 Aug;45(2):366-75. [PMID: 21057106]
9. Morin C, Fortin S, Cantin AM, et al. MAG-EPA resolves lung inflammation in an allergic model of asthma. *Clin Exp Allergy*. 2013 Sep;43(9):1071-82. [PMID: 23957343]
10. Morin C, Cantin AM, Rousseau É, et al. Pro-resolving action of MAG-DHA in lung inflammatory models related to cystic fibrosis. *Am J Respir Cell Mol Biol*. 2015 Oct;53(4):574-83. [PMID: 25781052]
11. Morin C, Fortin S, Rousseau É. New omega-3 derivatives reduce airway inflammation and prevent rho-kinase activation in an allergic model of asthma. *J Aller Ther*. 2012;3(S1):003. doi:10.4172/2155-6121.S1-003.
12. Morin C, Rousseau E, Blier PU, et al. Effect of docosahexaenoic acid monoacylglyceride on systemic hypertension and cardiovascular dysfunction. *Am J Physiol Heart Circ Physiol*. 2015 Jul 1;309(1):H93-H102. [PMID: 25910811]
13. Weylandt KH, Chiu CY, Gomolka B, et al. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvins and protectin formation. *Prostaglandins Other Lipid Mediat*. 2012 Mar;97(3-4):73-82. [PMID: 22326554]
14. Guasch-Ferré M, Hu FB, Martínez-González MA, et al. Primary prevention of cardiovascular disease with a . *N Engl J Med*. 2013 Apr 4;368(14):1279-90. [PMID: 23432189]
15. Mayor S. reduces cardiovascular events in people with heart disease, study shows. *BMJ*. 2016 Apr 24;353:i2348. [PMID: 27114468]
16. Chiva-Blanch G, Badimon L, Estruch R. Latest evidence of the effects of cardiovascular disease. *Curr Atheroscler Rep*. 2014 Oct;16(10):446. [PMID: 25115436]
17. Fitó M, Cladellas M, de la Torre R, et al. Anti-inflammatory effect of virgin olive oil in stable coronary disease patients: a randomized, crossover, controlled trial. *Eur J Clin Nutr*. 2008 Apr;62(4):570-74. [PMID: 17375118]
18. Ruano J, López-Miranda J, de la Torre R, et al. Intake of phenol-rich virgin olive oil improves the postprandial prothrombotic profile in hypercholesterolemic patients. *Am J Clin Nutr*. 2007 Aug;86(2):341-46. [PMID: 17684203]
19. Gimeno E, de la Torre-Carbot K, Lamuela-Raventós RM, et al. Changes in the phenolic content of low density lipoprotein after olive oil consumption in men. A randomized crossover controlled trial. *Br J Nutr*. 2007 Dec;98(6):1243-50. [PMID: 17617938]
20. Bogani P, Galli C, Villa M, et al. Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. *Atherosclerosis*. 2007 Jan;190(1):181-86. [PMID: 16488419]
21. Guasch-Ferré M, Hu FB, Martínez-González MA, et al. Olive oil intake and risk of cardiovascular disease and mortality in the PREDIMED Study. *BMC Med*. 2014 May 13;12:78. [PMID: 24886626]
22. Castañer O, Covas MI, Khymenets O, et al. Protection of LDL from oxidation by olive oil polyphenols is associated with a downregulation of CD40-ligand expression and its downstream products in vivo in humans. *Am J Clin Nutr*. 2012 May;95(5):1238-44. [PMID: 22440854]
23. Raederstorff D. Antioxidant activity of olive polyphenols in humans: a review. *Int J Vitam Nutr Res*. 2009 May;79(3):152-65. [PMID: 20209466]

***These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.**